<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Lisinopril</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00722</strong>&#160; (APRD00560)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (<span class="caps">ACE</span>), the enzyme responsible for the conversion of angiotensin I (<span class="caps">ATI</span>) to angiotensin II (<span class="caps">ATII</span>). <span class="caps">ATII</span> regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (<span class="caps">RAAS</span>). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00722/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00722/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00722.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00722.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00722.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00722.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00722.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00722">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Lisinopril</td><td>French/German/Spanish</td><td>INN</td></tr><tr><td>Lisinoprilum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Acebitor</td><td>GlaxoSmithKline</td></tr><tr><td>Acemin</td><td>AstraZeneca</td></tr><tr><td>Acerbon</td><td>AstraZeneca</td></tr><tr><td>Acinopril</td><td>sanofi-aventis</td></tr><tr><td>Bellisin</td><td>Ranbaxy</td></tr><tr><td>Biopril</td><td>Biochem</td></tr><tr><td>Dapril</td><td>Medochemie</td></tr><tr><td>Fibsol</td><td>Sigma</td></tr><tr><td>Fisopril</td><td>Sanofi-Aventis</td></tr><tr><td>Hipril</td><td>Micro Labs</td></tr><tr><td>Linopril</td><td>Klinger (Brazil)</td></tr><tr><td>Lisipril</td><td>Hexal (Czech Republic), Orion (Finland)</td></tr><tr><td>Noperten</td><td>Dexa (Indonesia)</td></tr><tr><td>Presiten</td><td>Magnachem</td></tr><tr><td>Prinivil</td><td>Merck Frosst</td></tr><tr><td>Ranolip</td><td>Ranbaxy</td></tr><tr><td>Ranopril</td><td>Ranbaxy</td></tr><tr><td>Rantex</td><td>Biotech</td></tr><tr><td>Sinopren</td><td>Ranbaxy</td></tr><tr><td>Sinopril</td><td>Eczacibasi (Russia)</td></tr><tr><td>Tensopril</td><td>Merck</td></tr><tr><td>Zestril</td><td>AstraZeneca</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Acercomp</td><td>Lisinopril and Hydrochlorothiazide</td></tr><tr><td>Acerdil D</td><td>Lisinopril and Hydrochlorothiazide</td></tr><tr><td>Adco-Zetomax CO</td><td>Lisinopril and Hydrochlorothiazide</td></tr><tr><td>Amchek L</td><td>Lisinopril and Amlodipine</td></tr><tr><td>Amlace</td><td>Lisinopril and Amlodipine</td></tr><tr><td>Amlodac-L</td><td>Lisinopril and Amlodipine</td></tr><tr><td>Amlopres-L </td><td>Lisinopril and Amlodipine</td></tr><tr><td>Amlot-L</td><td>Lisinopril and Amlodipine</td></tr><tr><td>Amlovas-L</td><td>Lisinopril and Amlodipine</td></tr><tr><td>Amtas-LP</td><td>Lisinopril and Amlodipine</td></tr><tr><td>Lisinopril Comp</td><td>lisinopril + hydrochlorothiazide</td></tr><tr><td>Prinzide</td><td>lisinopril + hydrochlorothiazide</td></tr><tr><td>Zestoretic Tab 10/12.5mg</td><td>lisinopril + hydrochlorothiazide</td></tr><tr><td>Zestoretic Tab 20/12.5mg</td><td>lisinopril + hydrochlorothiazide</td></tr><tr><td>Zestoretic Tab 20/25mg</td><td>lisinopril + hydrochlorothiazide</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>83915-83-7</td></tr><tr><th>Weight</th><td>Average: 405.4879<br>Monoisotopic: 405.226371117</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>31</sub>N<sub>3</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>RLAWWYSOJDYHDC-BZSNNMDCSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids; Alpha Amino Acid Amides; Phenylpropylamines; Pyrrolidine Carboxylic Acids; Amino Fatty Acids; Dicarboxylic Acids and Derivatives; Tertiary Carboxylic Acid Amides; Tertiary Amines; Polyols; Dialkylamines; Polyamines; Carboxylic Acids; Enolates; Monoalkylamines</td></tr><tr><th>Substituents</th><td>n-acyl-alpha-amino acid; n-acyl-alpha amino acid or derivative; alpha-amino acid amide; alpha-amino acid or derivative; phenylpropylamine; pyrrolidine carboxylic acid; pyrrolidine carboxylic acid or derivative; dicarboxylic acid derivative; benzene; tertiary carboxylic acid amide; pyrrolidine; carboxamide group; polyol; tertiary amine; carboxylic acid; secondary amine; polyamine; enolate; secondary aliphatic amine; primary aliphatic amine; amine; primary amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of hypertension and symptomatic congestive heart failure. May be used in conjunction with thrombolytic agents, aspirin and/or &#946;-blockers to improve survival in hemodynamically stable individuals following myocardial infarction. May be used to slow the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy. </td></tr><tr><th>Pharmacodynamics</th><td>Lisinopril is an orally active ACE inhibitor that antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of lisinopril by causing increased vasodilation and decreased blood pressure.</td></tr><tr><th>Mechanism of action</th><td>There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Lisinopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Lisinopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. </td></tr><tr><th>Absorption</th><td>Approximately 25%, but widely variable between individuals (6 to 60%) in all doses tested (5-80 mg); absorption is unaffected by food</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Lisinopril does not appear to be bound to serum proteins other than ACE.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Does not undergo metabolism, excreted unchanged in urine. </p></td></tr><tr><th>Route of elimination</th><td>Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine.</td></tr><tr><th>Half life</th><td>Effective half life of accumulation following multiple dosing is 12 hours. </td></tr><tr><th>Clearance</th><td><ul>
	<li>10 L/h [child weighting 30 kg receiving doses of 0.1 to 0.2 mg/kg]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include severe hypotension, electrolyte disturbances, and renal failure. LD<sub>50</sub>= 2000 mg/kg(orally in rat). Most frequent adverse effects include headache, dizziness, cough, fatigue and diarrhea. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.6426</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8815</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7605</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6515</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9512</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.969</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8574</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8793</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7622</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.725</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8999</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9708</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9653</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8266</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9821</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9389
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.6844
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8723 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9641
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8708
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Actavis elizabeth llc</li>
<li>Apotex inc etobicoke site</li>
<li>Aurobindo pharma ltd</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Lek pharmaceuticals d d</li>
<li>Lupin ltd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Ranbaxy pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Vintage pharmaceuticals llc</li>
<li>Watson laboratories inc</li>
<li>West ward pharmaceutical corp</li>
<li>Wockhardt ltd</li>
<li>Merck research laboratories div merck co inc</li>
<li>Astrazeneca uk ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.aidarex.com">Aidarex Pharmacuticals LLC</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li><a href="http://www.blurx.us">Blu Pharmaceuticals LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Coupler Enterprises Inc.</li>
<li>Dept Health Central Pharmacy</li>
<li>DHHS Program Support Center Supply Service Center</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li><a href="http://www.gsms.us">Golden State Medical Supply Inc.</a></li>
<li><a href="http://www.greenstonellc.com">Greenstone LLC</a></li>
<li><a href="http://www.ghc.org">Group Health Cooperative</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>International Laboratories Inc.</li>
<li><a href="http://www.iprpharmaceuticals.com">IPR Pharmaceuticals Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lek.si">Lek Pharmaceuticals Inc.</a></li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.lupinpharmaceuticals.com">Lupin Pharmaceuticals Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neighborcare Repackaging Inc.</li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li>Professional Co.</li>
<li>Promex Medical Inc.</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.stat-scripts.com">Stat Scripts LLC</a></li>
<li>Talbert Medical Management Corp.</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li>Torpharm Inc.</li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>10 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>2.5 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>20 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>30 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>40 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1816">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1890">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1891">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1892">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1756">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00594">Amiloride</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The ACE inhibitor increases serum levels of lithium</td></tr><tr><td><a href="/drugs/DB01345">Potassium</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00421">Spironolactone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Tizanidine increases the risk of hypotension with the ACE inhibitor</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00384">Triamterene</a></td><td>Increased risk of hyperkalemia</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Herbs that may attenuate the antihypertensive effect of lisinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice. </li>
<li>High salt intake may attenuate the antihypertensive effect of lisinopril.</li>
<li>Lisinopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia. </li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>